31.07.2013 • News

DuPont Operating Profit Recedes by 16% in Q2

Sales of the DuPont group were virtually flat in Q2 2013, with the slight revenue setback of 1% to $9.8 billion blamed on poor pricing for the titanium dioxide business it plans to sell or spin off. Operating profit fell 16% year-on-year to $1.9 billion. Among business segments, Agriculture is credited with the best quarterly performance. For full year 2013, CEO Ellen Kullman said she expects DuPont to deliver earnings "modestly above 2012 results," thereby overcoming "steep declines" in the TiO2 market and economic headwinds in Europe. 

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

most read